Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Receives Consensus Recommendation of “Hold” from Analysts

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) has been given a consensus recommendation of “Hold” by the five analysts that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $27.40.

Several analysts recently weighed in on KMTS shares. BTIG Research restated a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research report on Tuesday, April 7th. The Goldman Sachs Group dropped their price objective on Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kestra Medical Technologies in a research report on Monday, March 23rd.

Kestra Medical Technologies Price Performance

Shares of KMTS stock opened at $20.55 on Tuesday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15. Kestra Medical Technologies has a twelve month low of $13.25 and a twelve month high of $30.00. The company has a market cap of $1.20 billion, a P/E ratio of -5.19 and a beta of 0.82. The business has a fifty day simple moving average of $21.34 and a 200 day simple moving average of $24.20.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative return on equity of 65.49% and a negative net margin of 171.87%.The business had revenue of $24.55 million for the quarter. The firm’s quarterly revenue was up 62.7% compared to the same quarter last year. On average, sell-side analysts forecast that Kestra Medical Technologies will post -2.34 EPS for the current fiscal year.

Insider Buying and Selling

In other Kestra Medical Technologies news, insider Brian Daniel Webster sold 15,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $20.04, for a total value of $300,600.00. Following the completion of the transaction, the insider directly owned 349,786 shares in the company, valued at approximately $7,009,711.44. This trade represents a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 45,000 shares of company stock valued at $988,650 in the last ninety days. 3.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Large investors have recently bought and sold shares of the company. Farther Finance Advisors LLC bought a new position in Kestra Medical Technologies in the fourth quarter valued at about $31,000. Russell Investments Group Ltd. raised its position in Kestra Medical Technologies by 43.5% in the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new position in Kestra Medical Technologies in the third quarter valued at about $48,000. BNP Paribas Financial Markets raised its position in Kestra Medical Technologies by 148.9% in the third quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after purchasing an additional 1,638 shares during the last quarter. Finally, Daiwa Securities Group Inc. bought a new position in Kestra Medical Technologies in the fourth quarter valued at about $72,000.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.